Reaction
Vitiligo reporting signals
As of the last recalculation, Vitiligo appears in 2,275 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 42.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 137 | 42.2 | 42.4 |
| Ipilimumab | 180 | 41.3 | 41.5 |
| Nivolumab | 256 | 27.2 | 27.2 |
| Ruxolitinib | 166 | 22.8 | 22.8 |
| Pembrolizumab | 219 | 21.0 | 21.0 |
| Alemtuzumab | 43 | 20.7 | 20.8 |
| Canakinumab | 18 | 15.3 | 15.4 |
| Anastrozole Tablets | 33 | 14.3 | 14.3 |
| Letrozole Tablets | 68 | 13.3 | 13.3 |
| Busulfan | 21 | 12.3 | 12.3 |
| Letrozole | 75 | 11.5 | 11.5 |
| Indomethacin | 15 | 10.4 | 10.4 |
| Atezolizumab | 40 | 9.6 | 9.6 |
| Anakinra | 17 | 9.4 | 9.4 |
| Dabrafenib | 21 | 9.2 | 9.2 |
| Calcium Gluconate | 12 | 9.2 | 9.2 |
| Fulvestrant | 31 | 8.7 | 8.7 |
| Itraconazole | 11 | 8.7 | 8.7 |
| Anastrozole | 34 | 8.6 | 8.6 |
| Cortisone Acetate | 11 | 8.2 | 8.2 |
| Gentamicin | 11 | 7.7 | 7.7 |
| Methylphenidate | 24 | 7.7 | 7.7 |
| Vemurafenib | 10 | 7.6 | 7.6 |
| Trametinib | 20 | 7.6 | 7.6 |
| Fludarabine Phosphate | 29 | 6.8 | 6.8 |
| Durvalumab | 15 | 6.8 | 6.8 |
| Adalimumab-Fkjp | 32 | 6.4 | 6.4 |
| Dextrose | 9 | 6.3 | 6.3 |
| Tranexamic Acid | 6 | 6.2 | 6.2 |
| Dextrose Monohydrate | 9 | 6.2 | 6.2 |
| Ivacaftor | 5 | 5.8 | 5.8 |
| Encorafenib | 6 | 5.6 | 5.6 |
| Ixekizumab | 21 | 5.2 | 5.2 |
| Nevirapine | 5 | 5.1 | 5.1 |
| Abemaciclib | 11 | 5.1 | 5.1 |
| Ixazomib | 15 | 4.8 | 4.8 |
| Baricitinib | 5 | 4.8 | 4.8 |
| Guselkumab | 17 | 4.4 | 4.4 |
| Temozolomide | 10 | 4.4 | 4.4 |
| Pemetrexed Disodium | 18 | 4.3 | 4.4 |
| Pemetrexed | 10 | 4.3 | 4.3 |
| Ustekinumab | 36 | 3.3 | 3.3 |
| Secukinumab | 53 | 3.1 | 3.1 |
| Dupilumab | 138 | 2.7 | 2.7 |
| Bimekizumab | 6 | 2.6 | 2.6 |
| Dornase Alfa | 5 | 2.3 | 2.3 |
| Apremilast | 20 | 1.3 | 1.3 |